More articles from Current Drug Therapy
- Omeprazole: a new drug for the treatment of acid^peptic diseases
Gastroesophageal reflux disease, Zollinger-Ellison syndrome, duodenal ulcer, and gastric ulcer are among the disorders that have responded to treatment with this agent—the first of a new class of gastric antisecretory drugs.
- Treating hypertension to prevent coronary disease
Past successes and failures in treating hypertension suggest ways to provide better overall therapy and reduce the incidence of coronary heart disease.
- Managing the hypertensive patient: reasonable goals
Any approach to treating hypertension should be based on multiple blood pressure readings to establish the diagnosis, aggressive nondrug therapy, and use of low doses when initiating drug therapy.
- Alpha- and beta-blocking agents: pharmacology and properties
Continued investigations into the multiple effects of certain alpha and beta blockers may provide clues to more effective treatment of hypertension.
- The continuing development of antihypertensive drugs
Selective alpha-1 blockers and multiple-action beta blockers hold promise for enhanced blood pressure control.
- Tailoring antihypertensive therapy in 1991
The trend is toward individualized treatment and away from rigid stepped care.
- Hypertension and the adrenergic system
The increasing role of adrenergic drugs may be related to the possibility that adrenergic system abnormalities contribute to the development of primary hypertension.
- The role of adrenergic drugs in antihypertensive therapy
The clinical effects of drugs in the adrenergic class can be predicted by the location of the alpha or beta receptors that the drug activates or inhibits.
- Isradipine in the treatment of hypertension: a clinical profile
A new calcium channel blocker is safe, well tolerated, and has long-term antihypertensive efficacy regardless of age or race, with no adverse effects on lipids, carbohydrate tolerance, or renal function.